TY - JOUR
T1 - Enhanced androgen sensitivity in serum-free medium of a subline of the LNCaP human prostate cancer cell line
AU - Kirschenbaum, Alexander
AU - Ren, Meiyue
AU - Levine, Alice C.
N1 - Funding Information:
This work was supported in part by grants from the American Federation for Aging Research and the Dr. Hans Schapira Fund for Urologic Research.
PY - 1993/9
Y1 - 1993/9
N2 - The LNCaP-Fast Growing Colony (FGC) human prostate cancer cell line proliferates in response to the addition of dihydrotestosterone (DHT) 10-10-10-8 M in charcoal-stripped serum-supplemented media. LNCaP-FGC cells will not attach or proliferate in serum-free conditions. LNCaP-FGC stock cultures were maintained in medium supplemented with 10% FBS and added DHT (10-9 M) for > 25 passages (6 months). The resultant subline was designated as LNCaP-ss (supersensitive) because of its ability to attach in serum-free medium and to proliferate in response to very low levels of DHT. LNCaP-ss cells were grown in serum-free medium and proliferation assessed after 2, 3, 5, and 7 days' treatment with DHT. Significant enhancement of growth was demonstrated after 7 days' treatment with DHT over a wide range of concentrations (DHT 10-15 - 10-7 M) with maximal stimulation (3 × control, p < .001) noted with DHT 10-14 M. Changing the medium during the course of the experiment decreased, but did not eliminate, the DHT-induced cellular proliferation. Scatchard analysis of binding studies with LNCaP-ss cells revealed that both the Kd for the androgen receptor (AR) and the number of AR sites/ cell were similar to the corresponding values reported for the parental line. AR mRNA levels in LNCaP-ss cells, as measured by RNase protection assay, were significantly down-regulated by 7 days' treatment with DHT 10-15, 10-13, and 10-9 M. We conclude that maintaining LNCaP-FGC cells for 6 months in medium supplemented with DHT resulted in the development of a subline, LNCaP-ss, which can attach and proliferate in serum-free medium. This subline is sensitive to very low levels of androgen, as evidenced by increased proliferation and down-regulation of AR mRNA levels. (Steroids 58:439-444, 1993).
AB - The LNCaP-Fast Growing Colony (FGC) human prostate cancer cell line proliferates in response to the addition of dihydrotestosterone (DHT) 10-10-10-8 M in charcoal-stripped serum-supplemented media. LNCaP-FGC cells will not attach or proliferate in serum-free conditions. LNCaP-FGC stock cultures were maintained in medium supplemented with 10% FBS and added DHT (10-9 M) for > 25 passages (6 months). The resultant subline was designated as LNCaP-ss (supersensitive) because of its ability to attach in serum-free medium and to proliferate in response to very low levels of DHT. LNCaP-ss cells were grown in serum-free medium and proliferation assessed after 2, 3, 5, and 7 days' treatment with DHT. Significant enhancement of growth was demonstrated after 7 days' treatment with DHT over a wide range of concentrations (DHT 10-15 - 10-7 M) with maximal stimulation (3 × control, p < .001) noted with DHT 10-14 M. Changing the medium during the course of the experiment decreased, but did not eliminate, the DHT-induced cellular proliferation. Scatchard analysis of binding studies with LNCaP-ss cells revealed that both the Kd for the androgen receptor (AR) and the number of AR sites/ cell were similar to the corresponding values reported for the parental line. AR mRNA levels in LNCaP-ss cells, as measured by RNase protection assay, were significantly down-regulated by 7 days' treatment with DHT 10-15, 10-13, and 10-9 M. We conclude that maintaining LNCaP-FGC cells for 6 months in medium supplemented with DHT resulted in the development of a subline, LNCaP-ss, which can attach and proliferate in serum-free medium. This subline is sensitive to very low levels of androgen, as evidenced by increased proliferation and down-regulation of AR mRNA levels. (Steroids 58:439-444, 1993).
KW - LNCaP
KW - androgens
KW - prostate cancer
KW - steroids
KW - supersensitive
UR - http://www.scopus.com/inward/record.url?scp=0027166371&partnerID=8YFLogxK
U2 - 10.1016/0039-128X(93)90084-Z
DO - 10.1016/0039-128X(93)90084-Z
M3 - Article
C2 - 8236330
AN - SCOPUS:0027166371
SN - 0039-128X
VL - 58
SP - 439
EP - 444
JO - Steroids
JF - Steroids
IS - 9
ER -